3[3]Frieder HA,Buckley MM-T. Torasemide-a review of its pharmacology, properties and therapeutic potential [J]. Drugs, 1991,41(1) :S81 - S103.
4[4]Bart WH,Smith HL,Karnes HT,et al.Torasemide dose proportionality of pharmacokinetics and pharmacodynamics [J]. Prog Pharmacol Clin Pharmacol, 1990,8: 29 - 37.
5[5]Fowler SF, Murray KM. Torsemide: A new loop diruetic [J].Am J Health-Syst Pharm, 1995,52(15): 1771 - 1780.
6[6]Knauf H,Spahn H,Mutschler E. The loop diuretic torasemide in chronic renal failure: pharmacokinetics and pharmacodynamics [J]. Drugs, 1991,41 (Suppl 3) :S23 - S34.
7[7]Kido H,Ohtaki Y. Torasemide (LUPRAC) :a review of its pharmacological and clinical profile[J]. Nippon Yakeurigaku Zasshi,2001,118(2):97- 105.
8[8]Kruck F. Acute and long term effects of loop diuretics in heart failure[J]. Drugs, 1991,41 (Suppl 3): S60 - S68.
9[9]Barr WH,Smith HL,Karnes HT,et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers[J]. Prog Pharmacol Clin Pharmmol, 1990 ;8:15 - 28.
10[10]Schwartz S,Brater DC,Pound D,et al. Bioavailability,pharmacokinetics and pharmacodynamics of torasemide in patients with cirrhosis[J]. Clin Pharmacol Ther, 1993,54(1): 90 - 97.
